SFRO Congres

Attendees, exhibitors & solutions

Who this event is for

Industry trends

Key trends shaping this market and its wider industry.

Arrival airports

Choose from the following airports, with convenient access to the event and venue.

Hotel tiers

A range of accommodation options near the venue and across key areas.

Local transport

Get around the city with these convenient transport options.

Frequently asked

Glossary

1

Radiotherapy (RT)

Treatment using ionising radiation to control or destroy cancer cells while sparing surrounding healthy tissue. At SFRO 2026, sessions cover technical delivery, fractionation and clinical indications.

2

Radiation oncology

The medical specialty that combines radiation physics, imaging and clinical oncology to plan and deliver radiotherapy. SFRO is the French society for this specialty.

3

IMRT

Intensity-modulated radiotherapy. A delivery technique that shapes radiation dose to the tumour by varying beam intensity, commonly used for head and neck, prostate and pelvic tumours.

4

VMAT

Volumetric modulated arc therapy. An arc-based form of IMRT that rotates the treatment machine around the patient, often reducing treatment time compared with fixed-field IMRT.

5

SBRT

Stereotactic body radiotherapy. High-dose, tightly focused treatment delivered in a small number of fractions, used for selected lung, liver, prostate and oligometastatic lesions.

6

IGRT

Image-guided radiotherapy. Daily or intra-fraction imaging used to verify patient and tumour position before treatment, improving targeting accuracy.

7

Brachytherapy

Internal radiotherapy delivered by placing a radioactive source close to or inside the tumour, commonly used in gynaecological, prostate and breast treatments.

8

Proton therapy

Particle therapy using protons to deposit dose at a defined depth with a sharp distal fall-off, of interest for paediatric and skull-base tumours.

9

Adaptive radiotherapy

Replanning treatment during a course of radiotherapy to account for tumour shrinkage, weight loss or organ motion, often using daily imaging.

10

Hypofractionation

Delivery of a larger dose per fraction in fewer sessions. It is a major theme in breast, prostate and palliative radiotherapy practice.

11

Target volume (GTV, CTV, PTV)

The gross tumour volume (GTV), clinical target volume (CTV) and planning target volume (PTV) are nested volumes used to prescribe and plan dose while accounting for microscopic spread and set-up uncertainty.

12

Organ at risk (OAR)

Healthy structures close to the target whose radiation dose must be constrained to reduce toxicity, for example the spinal cord, parotid glands or rectum.

13

DVH

Dose-volume histogram. A graphical tool that summarises how much dose is delivered to a target volume or organ at risk during a radiotherapy plan.

14

Medical physics

The discipline covering dosimetry, treatment planning, quality assurance and equipment commissioning. Medical physicists are core participants in SFRO technical and scientific sessions.

15

Dosimetry

Measurement and calculation of radiation dose. Accurate dosimetry underpins safe delivery in external beam radiotherapy and brachytherapy.

16

Radiomics

Extraction of quantitative imaging features from CT, MRI or PET scans to build predictive models for treatment response and toxicity.

17

FLASH radiotherapy

Experimental ultra-high dose-rate irradiation that may reduce normal-tissue damage while maintaining tumour control. It is an active research topic at European radiotherapy meetings.

18

Oligometastatic disease

A limited number of metastatic lesions that may be treated with local therapy such as SBRT or surgery, often discussed in multidisciplinary tumour boards.

19

MDT

Multidisciplinary team meeting where radiation oncologists, surgeons, medical oncologists, radiologists and pathologists agree on treatment strategy for individual patients.

20

Quality assurance (QA)

Planned checks on equipment, planning systems, imaging and treatment delivery to ensure consistent and safe radiotherapy. QA is relevant to both clinical and industry sessions.